Vaccitech To Present Final Data At EASL Congress For Phase 1b/2 HBV002 Study In Adults With Chronic Hepatitis B
Portfolio Pulse from Happy Mohamed
Vaccitech plc (NASDAQ:VACC) will present positive final data from the HBV002 clinical trial at the EASL Congress 2023. The trial evaluated VTP-300 in adults with chronic Hepatitis B, showing meaningful and durable reductions of HBsAg. VTP-300 led to a decline in HBsAg in adults with chronic Hepatitis B with either genotype B or C viruses.
June 21, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaccitech's VTP-300 showed promising results in the HBV002 clinical trial, with meaningful and durable reductions of HBsAg in adults with chronic Hepatitis B. This could potentially lead to increased interest in the company's stock.
The positive final data from the HBV002 clinical trial demonstrates the potential of Vaccitech's VTP-300 in treating chronic Hepatitis B. This could lead to increased interest in the company's stock as investors may see potential growth in the company's product pipeline and future earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100